Roche Holding AG said it will pay $725 million in cash to buy Seragon Pharmaceuticals, a privately-held biotech company that researches breast cancer treatments, and may pay up to another $1 billion based on certain milestones. Roche has a strong suite of cancer drugs and has pushed ahead with plans to develop "follow-on" medicines it hopes will replace or breathe new life into older treatments. Seragon was spun out from Aragon Pharmaceuticals last year when that firm was bought for up to $1 billion by Johnson & Johnson.
via Business News - Yahoo Finance http://ift.tt/1qjfpJ8
0 commentaires:
Enregistrer un commentaire